Market Overview:
The global rapid-dissolving tablets market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, and technological advancements in the pharmaceutical industry. Based on type, the global rapid-dissolving tablets market is segmented into anti-psychotics drugs, anti-epileptics drugs, and other types. The anti-psychotics drug segment is expected to account for the largest share of the global market in 2018. This growth can be attributed to factors such as rising incidence of mental disorders and growing awareness about these disorders among people across the globe. Based on application,the global rapid-dissolving tablets market is segmented into CNS diseases, gastrointestinal diseases, CVS diseases (cardiovascular system), and other applications.
Product Definition:
A tablet that dissolves rapidly in the mouth, typically within a few seconds. They are often used to provide relief from pain, nausea, or indigestion.
Anti-Psychotics Drug:
Anti-psychotics drug is a group of medicines used to treat mental disorders such as schizophrenia, mania, and bipolar disorder. Anti-psychotics drugs are also used in the treatment of severe depression and anxiety disorders. The global anti-psychotics drug market is expected to grow at a significant rate owing to increasing prevalence rates of schizophrenia and bipolar disorder coupled with growing awareness levels about the available treatments for these diseases among consumers across the globe.
Anti-Epileptics Drug:
Anti-epileptics drugs are used to prevent seizures and/or to reduce the duration and severity of seizures. Anti-epileptic drugs can be divided into two classes, namely antiepileptogenic agents (AEDs), which are primarily employed in the treatment of epileptic seizures, and anti-epileptic agents (AEPIs), which are used as a therapy for various conditions associated with epilepsy such as focal epilepsy.
Application Insights:
Based on application, the global market is segmented into CNS diseases, gastrointestinal diseases, cardiovascular diseases (CVDs), chronic venous sinus disease (CVS), and others. The CNS drugs segment dominated the market in 2017 owing to high prevalence of neurological disorders such as Alzheimer¢â‚¬â„¢s disease and Parkinson¢â‚¬â„¢s disease. According to estimates reported by WHO in 2018, there are approximately 50 million people suffering from dementia worldwide. Furthermore, with an increase in life expectancy across the globe due to improved healthcare standards and sanitation facilities coupled with a rise in the number of older population groups is expected to fuel demand for rapid-dissolving tablets over the forecast period.
The gastrointestinal diseases segment is expected register significant growth over next eight years owing to increasing incidence of conditions such as irritable bowel syndrome (IBS).
Regional Analysis:
Asia Pacific dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing awareness about mental health and availability of treatment options. In addition, rising disposable income levels and improving healthcare infrastructure are also likely to contribute toward industry growth over the coming years.
The Asia Pacific market for rapid-dissolving tablets is anticipated to grow at a significant rate during the forecast period owing to factors such as growing population, rising incidence of CNS disorders, increasing prevalence of CVDs & diabetes, and expanding geriatric population base.
Growth Factors:
- Increasing demand for convenience foods: The modern lifestyle is characterized by busy schedules and a lack of time for preparing meals. This has led to an increase in the demand for convenience foods, such as rapid-dissolving tablets.
- Rising prevalence of chronic diseases: The prevalence of chronic diseases is increasing due to changing lifestyles and environmental factors. This is leading to an increase in the use of medications, which is driving the growth of the rapid-dissolving tablets market.
- Growing awareness about health and wellness: There is a growing awareness among consumers about the importance of maintaining good health and preventing chronic diseases through healthy eating habits and regular exercise. This is leading to an increase in the demand for healthy food products, including rapid-dissolving tablets.
- Technological advancements: Rapid-dissolving tablet technology continues to evolve with new product innovations being launched regularly into the market place .This has resulted in increased consumer acceptance and higher adoption rates across various applications segments 5) Emerging markets offer significant growth potential: The rapid-dissoling tablet market offers significant growth potential in emerging markets such as India, China, Brazil, Mexico etc., due to rising disposable incomes and expanding population bases
Scope Of The Report
Report Attributes
Report Details
Report Title
Rapid-dissolving Tablets Market Research Report
By Type
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
By Application
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
By Companies
Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Conquer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Rapid-dissolving Tablets Market Report Segments:
The global Rapid-dissolving Tablets market is segmented on the basis of:
Types
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Merck
- Mylan
- Pfizer
- Johnson and Johnson
- GSK
- Otsuka
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Conquer
Highlights of The Rapid-dissolving Tablets Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
- By Application:
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rapid-dissolving Tablets Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rapid-dissolving tablets are a type of medication that dissolve quickly in the mouth. They are used to treat conditions such as diarrhea, constipation, and stomach pain.
Some of the key players operating in the rapid-dissolving‚â tablets market are Teva, Merck, Mylan, Pfizer, Johnson and Johnson, GSK, Otsuka, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Conquer.
The rapid-dissolving‚ tablets market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Rapid-dissolving Tablets Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rapid-dissolving Tablets Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rapid-dissolving Tablets Market - Supply Chain
4.5. Global Rapid-dissolving Tablets Market Forecast
4.5.1. Rapid-dissolving Tablets Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rapid-dissolving Tablets Market Size (000 Units) and Y-o-Y Growth
4.5.3. Rapid-dissolving Tablets Market Absolute $ Opportunity
5. Global Rapid-dissolving Tablets Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Rapid-dissolving Tablets Market Size and Volume Forecast by Type
5.3.1. Anti-Psychotics Drug
5.3.2. Anti-Epileptics Drug
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Rapid-dissolving Tablets Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Rapid-dissolving Tablets Market Size and Volume Forecast by Application
6.3.1. CNS Diseases
6.3.2. Gastrointestinal Diseases
6.3.3. CVS Diseases
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Rapid-dissolving Tablets Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Rapid-dissolving Tablets Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Rapid-dissolving Tablets Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rapid-dissolving Tablets Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rapid-dissolving Tablets Demand Share Forecast, 2019-2026
9. North America Rapid-dissolving Tablets Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rapid-dissolving Tablets Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rapid-dissolving Tablets Market Size and Volume Forecast by Application
9.4.1. CNS Diseases
9.4.2. Gastrointestinal Diseases
9.4.3. CVS Diseases
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Rapid-dissolving Tablets Market Size and Volume Forecast by Type
9.7.1. Anti-Psychotics Drug
9.7.2. Anti-Epileptics Drug
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Rapid-dissolving Tablets Demand Share Forecast, 2019-2026
10. Latin America Rapid-dissolving Tablets Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rapid-dissolving Tablets Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rapid-dissolving Tablets Market Size and Volume Forecast by Application
10.4.1. CNS Diseases
10.4.2. Gastrointestinal Diseases
10.4.3. CVS Diseases
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Rapid-dissolving Tablets Market Size and Volume Forecast by Type
10.7.1. Anti-Psychotics Drug
10.7.2. Anti-Epileptics Drug
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Rapid-dissolving Tablets Demand Share Forecast, 2019-2026
11. Europe Rapid-dissolving Tablets Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rapid-dissolving Tablets Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rapid-dissolving Tablets Market Size and Volume Forecast by Application
11.4.1. CNS Diseases
11.4.2. Gastrointestinal Diseases
11.4.3. CVS Diseases
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Rapid-dissolving Tablets Market Size and Volume Forecast by Type
11.7.1. Anti-Psychotics Drug
11.7.2. Anti-Epileptics Drug
11.7.3. Oher
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Rapid-dissolving Tablets Demand Share, 2019-2026
12. Asia Pacific Rapid-dissolving Tablets Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rapid-dissolving Tablets Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rapid-dissolving Tablets Market Size and Volume Forecast by Application
12.4.1. CNS Diseases
12.4.2. Gastrointestinal Diseases
12.4.3. CVS Diseases
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Rapid-dissolving Tablets Market Size and Volume Forecast by Type
12.7.1. Anti-Psychotics Drug
12.7.2. Anti-Epileptics Drug
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Rapid-dissolving Tablets Demand Share, 2019-2026
13. Middle East & Africa Rapid-dissolving Tablets Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Rapid-dissolving Tablets Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rapid-dissolving Tablets Market Size and Volume Forecast by Application
13.4.1. CNS Diseases
13.4.2. Gastrointestinal Diseases
13.4.3. CVS Diseases
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Rapid-dissolving Tablets Market Size and Volume Forecast by Type
13.7.1. Anti-Psychotics Drug
13.7.2. Anti-Epileptics Drug
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Rapid-dissolving Tablets Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Rapid-dissolving Tablets Market: Market Share Analysis
14.2. Rapid-dissolving Tablets Distributors and Customers
14.3. Rapid-dissolving Tablets Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Johnson and Johnson
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GSK
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Otsuka
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly and Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. AstraZeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bristol-Myers Squibb
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Conquer
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
